JPS61122214A - 抗リウマチ剤 - Google Patents
抗リウマチ剤Info
- Publication number
- JPS61122214A JPS61122214A JP24564984A JP24564984A JPS61122214A JP S61122214 A JPS61122214 A JP S61122214A JP 24564984 A JP24564984 A JP 24564984A JP 24564984 A JP24564984 A JP 24564984A JP S61122214 A JPS61122214 A JP S61122214A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- antirheumatic
- day
- active ingredient
- man
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003435 antirheumatic agent Substances 0.000 title claims abstract description 8
- 230000003356 anti-rheumatic effect Effects 0.000 title abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 claims abstract description 4
- FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 claims abstract description 3
- 239000004046 24R,25-dihydroxy-cholecalciferol Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 15
- 239000003921 oil Substances 0.000 abstract description 5
- 235000019198 oils Nutrition 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000002775 capsule Substances 0.000 abstract description 3
- 239000007900 aqueous suspension Substances 0.000 abstract description 2
- 239000002285 corn oil Substances 0.000 abstract description 2
- 235000005687 corn oil Nutrition 0.000 abstract description 2
- 235000012343 cottonseed oil Nutrition 0.000 abstract description 2
- 239000002385 cottonseed oil Substances 0.000 abstract description 2
- 150000002148 esters Chemical class 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000000829 suppository Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 244000105624 Arachis hypogaea Species 0.000 abstract 1
- 239000000428 dust Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 235000020232 peanut Nutrition 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- -1 triglyceride ester Chemical class 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- WFDKAKYREYOPOC-UHFFFAOYSA-N ethyl 4-hydroxybenzoate titanium Chemical compound [Ti].C(C)OC(=O)C1=CC=C(O)C=C1 WFDKAKYREYOPOC-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24564984A JPS61122214A (ja) | 1984-11-20 | 1984-11-20 | 抗リウマチ剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24564984A JPS61122214A (ja) | 1984-11-20 | 1984-11-20 | 抗リウマチ剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61122214A true JPS61122214A (ja) | 1986-06-10 |
| JPS6259091B2 JPS6259091B2 (enrdf_load_stackoverflow) | 1987-12-09 |
Family
ID=17136778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24564984A Granted JPS61122214A (ja) | 1984-11-20 | 1984-11-20 | 抗リウマチ剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61122214A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142476A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇混悬剂及其制备方法 |
-
1984
- 1984-11-20 JP JP24564984A patent/JPS61122214A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142476A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇混悬剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6259091B2 (enrdf_load_stackoverflow) | 1987-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schwartz et al. | Metabolic and renal studies in chronic potassium depletion resulting from overuse of laxatives | |
| Smith | On the interruption of pregnancy in the rat by the injection of ovarian follicular extract | |
| JPS6089422A (ja) | 抗骨粗鬆症剤 | |
| WO1995017889A1 (fr) | Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle | |
| EP0136464B1 (en) | Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts | |
| Ellinger et al. | Nicotinamide Deficiency after Oral Penicillin | |
| TH et al. | Clinical investigations of fluothane. | |
| Abrahams et al. | Fatal Case of Acute Porphyria | |
| JPS61122214A (ja) | 抗リウマチ剤 | |
| Duvoisin | Antagonism of levodopa by papaverine | |
| EP0276573A2 (en) | Use of 24,25-dihydroxycholecalciferol in the prophylaxis of bone senescence | |
| JPS61129130A (ja) | 抗尿毒症剤 | |
| Czerwinski et al. | Safety and efficacy of zinc sulfate in geriatric patients | |
| JPH0616548A (ja) | 組織異常増殖抑制剤 | |
| JP2543627B2 (ja) | 活性型ビタミンｄ含有治療剤 | |
| JP2876547B2 (ja) | 抗クル病剤 | |
| JPH0372206B2 (enrdf_load_stackoverflow) | ||
| JPS6391323A (ja) | 抗尿路結石症剤 | |
| JPS5843385B2 (ja) | シジミの薬効成分及びその製造法 | |
| JPS61109721A (ja) | 骨粗しよう症における疼痛軽減剤 | |
| Mraz et al. | The role of myocardial glycogen content for the development of isoprenaline-induced myocardial lesions in different inbred strains of rats | |
| JPS61130226A (ja) | 異所性石灰化における疼痛軽減剤 | |
| JPS61130227A (ja) | 腫瘍における疼痛軽減剤 | |
| Pearl et al. | Propranolol treatment of thyrotoxicosis in a premature infant | |
| JPH0371412B2 (enrdf_load_stackoverflow) |